Melatonin as an Anti-cancer Agent: Time of
Administration May Be Critical

Russel J Reiter

Short Communication

Melatonin as an Anti-cancer Agent: Time of Administration May Be Critical

Russel J Reiter*

Department of Cell Systems and Anatomy, UT Health, Long School of Medicine, San Antonio, Texas, USA

Corresponding Author

Received Date:December 12, 2023; Published Date:January 10, 2024

Abstract

The scientific literature is replete with publications documenting the cancer inhibitory activity of the endogenouslyproduced molecule, melatonin. While this has been documented for many cancer types [1], much of the research has been directed to the role of melatonin in suppressing the initiation, progression and metastasis of breast cancer [2].

Download PDF
View FullText

Article Details

ISSN: 2688-8203
DOI: 10.33552/ACRCI.2023.04.000583
Volume 4 - Issue 2, 2023
Open Access

Citation

Russel J Reiter*. Melatonin as an Anti-cancer Agent: Time of Administration May Be Critical. Adv Can Res & Clinical Imag. 4(2): 2024. ACRCI.MS.ID.000583.